Keyword search (3,172 papers available)


Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.

Author(s): DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E...

To determine the extent of metabotropic glutamate receptor type 5 (mGluR5) network abnormalities associated with focal cortical dysplasia (FCD), we performed graph theoretical analysis of [11C]ABP6...

Article GUID: 33401137

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith...

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP,...

Article GUID: 32725777

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment

Author(s): Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G,...

INTRODUCTION: Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown...

Article GUID: 32582834

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

Author(s): Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestik...

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162 Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mesti...

Article GUID: 32559027

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Author(s): Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Les...

Nat Commun. 2019 Sep 17;10(1):4227 Authors: Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, ...

Article GUID: 31530809

Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study.

Author(s): Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E

Front Neurosci. 2019;13:875 Authors: Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E

Article GUID: 31507359

Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

Author(s): DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Cereb Cortex. 2016 10 17;26(11):4170-4179 Authors: DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Article GUID: 27578494

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Author(s): Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Mol Psychiatry. 2017 11;22(11):1531-1538 Authors: Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Article GUID: 28894304

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Author(s): Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s ...

Eur J Nucl Med Mol Imaging. 2018 06;45(6):1021-1030 Authors: Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheim...

Article GUID: 29396637


Title:Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.
Authors:Smart KNagano-Saito AMilella MSSakae DYFavier MVigneault ELouie LHamilton AFerguson SSGRosa-Neto PNarayanan SEl Mestikawy SLeyton MBenkelfat C
Link:https://www.ncbi.nlm.nih.gov/pubmed/32559027?dopt=Abstract
Category:J Psychiatry Neurosci
PMID:32559027
Dept Affiliation: CSBN
1 From the Department of Psychiatry, McGill University, Montreal, Que. (Smart, Nagano-Saito, Milella, Sakae, Favier, Vigneault, Louie, Rosa-Neto, El Mestikawy, Leyton, Benkelfat); the Douglas Mental Health University Institute, McGill University, Montreal, Que. (Smart, Sakae, Favier, Vigneault, Rosa-Neto, El Mestikawy); the Department of Cellular and Molecular Medicine, University of Ottawa, Ont. (Hamilton, Ferguson); the McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); and the Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Que. (Leyton).

Description:

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162

Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C

Abstract

Background: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood.

Methods: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [3H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [11C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence.

Results: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neur.

Limitations: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences.

Conclusion: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization.

PMID: 32559027 [PubMed - as supplied by publisher]